Quick Answer: Guidelines recommend considering GLP-1 receptor agonists for weight regain after bariatric surgery when BMI remains 27 kg/m with comorbidities or 30 kg/m, lifestyle modifications are insufficient, and no anatomical complications require surgical revision
(This is associative evidence and may reflect confounding by indication, surveillance patterns, and glycaemic differences.) For post-marketing pharmacovigilance, FAERS-based analyses of semaglutide identify multiple safety signals (e.g., gastrointestinal obstruction-related terms, dehydration/volume depletion in some GLP-1RA analyses), but vulvovaginal dryness/infection/discharge/pain are not prominent as labelled risks in the major semaglutide FAERS disproportionality paper retrieved here
Good candidates typically have a BMI over 30, or a BMI of 27 or higher along with one or more weight-related health conditions such as type 2 diabetes, high blood pressure, or high cholesterol
Neither figure is tied to a named third-party platform on that page itself
